切除不能肝細胞がん市場：全身治療、エンドユーザー別-2023-2030年の世界予測

切除不能肝細胞がんの世界市場は、2023年にCAGR 13.31%で16億8,300万米ドルが予測され、2030年には40億5,400万米ドルに達するという驚異的な成長を遂げると予測されています。

FPNVポジショニング・マトリックス

FPNVポジショニングマトリックスは世界の切除不能肝細胞がん市場を評価するために不可欠です。事業戦略や製品満足度などの主要指標を検証することで、ベンダーの包括的な評価を提供し、ユーザーが特定のニーズに基づいて情報に基づいた意思決定を行えるようにします。この高度な分析により、ベンダーは成功の度合いが異なる4つの象限に整理されます：フォアフロント（F）、パスファインダー（P）、ニッチ（N）、バイタル（V）です。

市場シェア分析

市場シェア分析では、特定の市場領域におけるベンダーの現状を洞察することができます。全体的な収益、顧客基盤、その他の主要指標に対するベンダーの貢献度を比較することで、企業が市場シェアを争う際に、自社の業績や直面している状況をより深く理解することができます。また、本分析では、調査した基準年において、特定のセクターがどの程度競合しているのか、蓄積、断片化の優位性、合併の特徴についても明らかにしています。

本レポートは、以下のポイントに関する洞察を提供します：

1.市場の浸透度：主要企業が提供する市場に関する包括的な情報を提供します。

2.市場の発展：有利な新興市場に関する詳細情報を提供し、市場の成熟セグメントにおける浸透度を分析します。

3.市場の多様化：新製品の上市、未開発地域、最近の開発、投資に関する詳細情報を提供します。

4.市場の動向：COVID-19、ロシア・ウクライナ紛争、高インフレの累積的な影響を包括的に理解することができます。

5.競合の評価と情報：主要企業の市場シェア、戦略、製品、認証、規制状況、特許状況、製造能力を網羅的に評価します。

6.製品開発およびイノベーション：将来技術、研究開発活動、画期的な製品開発に関する知的洞察を提供します。

本レポートは、以下のような質問にお答えします：

1.切除不能肝細胞がんの世界市場規模および予測は？

2.予測期間中、世界の切除不能肝細胞がん市場を形成するCOVID-19の阻害要因と影響は？

3.切除不能肝細胞がんの世界市場において予測期間中に投資すべき製品/セグメント/アプリケーション/分野は？

4.切除不能肝細胞がんの世界市場における競争戦略は？

5.切除不能肝細胞がんの世界市場における技術動向と規制の枠組みは？

6.切除不能肝細胞がんの世界市場における主要ベンダーの市場シェアは？

7.切除不能肝細胞がんの世界市場への参入には、どのような形態や戦略的な動きが適していると考えられるか？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 肝がんの発生率が高い
    • 肝臓がんの増加
    • 化学療法の主な応用
  • 抑制要因
    • 切除不能肝細胞がんの限定診断
  • 機会
    • 新しい治療法と療法の進歩
  • 課題
    • 現在の治療法の効果は限定的
• 市場動向
• COVID-19の累積的な影響
• ロシア・ウクライナ紛争の累積的影響
• 高インフレの累積的影響
• ポーターのファイブフォース分析
• バリューチェーンとクリティカルパス分析
• 規制の枠組み
• 顧客のカスタマイズ

第6章 切除不能肝細胞がん市場全身治療別

• 化学療法
• 免疫療法
• 分子標的療法

第7章 切除不能肝細胞がん市場：エンドユーザー別

• がんセンター
• 病院
• 調査機関
• 専門クリニック

第8章 南北アメリカの切除不能肝細胞がん市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第9章 アジア太平洋地域の切除不能肝細胞がん市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第10章 欧州・中東・アフリカの切除不能肝細胞がん市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第11章 競合情勢

• FPNVポジショニングマトリクス
• 市場シェア分析：主要企業別
• 競合シナリオ分析：主要企業別

第12章 掲載企業一覧

第13章 付録

• ディスカッションガイド
• ライセンスと価格について

LIST OF FIGURES

• FIGURE 1. UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET RESEARCH PROCESS
• FIGURE 2. UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, 2022 VS 2030
• FIGURE 3. UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY SYSTEMIC TREATMENT, 2022 VS 2030 (%)
• FIGURE 5. UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY END USER, 2022 VS 2030 (%)
• FIGURE 6. UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY REGION, 2022 VS 2030 (%)
• FIGURE 7. UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET DYNAMICS
• FIGURE 8. UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY SYSTEMIC TREATMENT, 2022 VS 2023 VS 2030 (USD MILLION)
• FIGURE 9. UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY END USER, 2022 VS 2023 VS 2030 (USD MILLION)
• FIGURE 10. AMERICAS UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
• FIGURE 11. UNITED STATES UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY STATE, 2022 VS 2023 VS 2030 (USD MILLION)
• FIGURE 12. ASIA-PACIFIC UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
• FIGURE 13. EUROPE, MIDDLE EAST & AFRICA UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
• FIGURE 14. UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET, FPNV POSITIONING MATRIX, 2022
• FIGURE 15. UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SHARE, BY KEY PLAYER, 2022

LIST OF TABLES

• TABLE 1. UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2022
• TABLE 3. UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY SYSTEMIC TREATMENT, 2018-2030 (USD MILLION)
• TABLE 5. UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 6. UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 7. UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY MOLECULARLY TARGETED THERAPY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 8. UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 9. UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY CANCER CENTERS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 12. UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. AMERICAS UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 14. AMERICAS UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY SYSTEMIC TREATMENT, 2018-2030 (USD MILLION)
• TABLE 15. AMERICAS UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 16. ARGENTINA UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY SYSTEMIC TREATMENT, 2018-2030 (USD MILLION)
• TABLE 17. ARGENTINA UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 18. BRAZIL UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY SYSTEMIC TREATMENT, 2018-2030 (USD MILLION)
• TABLE 19. BRAZIL UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 20. CANADA UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY SYSTEMIC TREATMENT, 2018-2030 (USD MILLION)
• TABLE 21. CANADA UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 22. MEXICO UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY SYSTEMIC TREATMENT, 2018-2030 (USD MILLION)
• TABLE 23. MEXICO UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 24. UNITED STATES UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 25. UNITED STATES UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY SYSTEMIC TREATMENT, 2018-2030 (USD MILLION)
• TABLE 26. UNITED STATES UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 27. ASIA-PACIFIC UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 28. ASIA-PACIFIC UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY SYSTEMIC TREATMENT, 2018-2030 (USD MILLION)
• TABLE 29. ASIA-PACIFIC UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 30. AUSTRALIA UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY SYSTEMIC TREATMENT, 2018-2030 (USD MILLION)
• TABLE 31. AUSTRALIA UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 32. CHINA UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY SYSTEMIC TREATMENT, 2018-2030 (USD MILLION)
• TABLE 33. CHINA UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 34. INDIA UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY SYSTEMIC TREATMENT, 2018-2030 (USD MILLION)
• TABLE 35. INDIA UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 36. INDONESIA UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY SYSTEMIC TREATMENT, 2018-2030 (USD MILLION)
• TABLE 37. INDONESIA UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 38. JAPAN UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY SYSTEMIC TREATMENT, 2018-2030 (USD MILLION)
• TABLE 39. JAPAN UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 40. MALAYSIA UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY SYSTEMIC TREATMENT, 2018-2030 (USD MILLION)
• TABLE 41. MALAYSIA UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 42. PHILIPPINES UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY SYSTEMIC TREATMENT, 2018-2030 (USD MILLION)
• TABLE 43. PHILIPPINES UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 44. SINGAPORE UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY SYSTEMIC TREATMENT, 2018-2030 (USD MILLION)
• TABLE 45. SINGAPORE UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 46. SOUTH KOREA UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY SYSTEMIC TREATMENT, 2018-2030 (USD MILLION)
• TABLE 47. SOUTH KOREA UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 48. TAIWAN UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY SYSTEMIC TREATMENT, 2018-2030 (USD MILLION)
• TABLE 49. TAIWAN UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 50. THAILAND UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY SYSTEMIC TREATMENT, 2018-2030 (USD MILLION)
• TABLE 51. THAILAND UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 52. VIETNAM UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY SYSTEMIC TREATMENT, 2018-2030 (USD MILLION)
• TABLE 53. VIETNAM UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 54. EUROPE, MIDDLE EAST & AFRICA UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 55. EUROPE, MIDDLE EAST & AFRICA UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY SYSTEMIC TREATMENT, 2018-2030 (USD MILLION)
• TABLE 56. EUROPE, MIDDLE EAST & AFRICA UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 57. DENMARK UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY SYSTEMIC TREATMENT, 2018-2030 (USD MILLION)
• TABLE 58. DENMARK UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 59. EGYPT UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY SYSTEMIC TREATMENT, 2018-2030 (USD MILLION)
• TABLE 60. EGYPT UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 61. FINLAND UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY SYSTEMIC TREATMENT, 2018-2030 (USD MILLION)
• TABLE 62. FINLAND UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 63. FRANCE UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY SYSTEMIC TREATMENT, 2018-2030 (USD MILLION)
• TABLE 64. FRANCE UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 65. GERMANY UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY SYSTEMIC TREATMENT, 2018-2030 (USD MILLION)
• TABLE 66. GERMANY UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 67. ISRAEL UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY SYSTEMIC TREATMENT, 2018-2030 (USD MILLION)
• TABLE 68. ISRAEL UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 69. ITALY UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY SYSTEMIC TREATMENT, 2018-2030 (USD MILLION)
• TABLE 70. ITALY UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 71. NETHERLANDS UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY SYSTEMIC TREATMENT, 2018-2030 (USD MILLION)
• TABLE 72. NETHERLANDS UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 73. NIGERIA UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY SYSTEMIC TREATMENT, 2018-2030 (USD MILLION)
• TABLE 74. NIGERIA UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 75. NORWAY UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY SYSTEMIC TREATMENT, 2018-2030 (USD MILLION)
• TABLE 76. NORWAY UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 77. POLAND UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY SYSTEMIC TREATMENT, 2018-2030 (USD MILLION)
• TABLE 78. POLAND UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 79. QATAR UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY SYSTEMIC TREATMENT, 2018-2030 (USD MILLION)
• TABLE 80. QATAR UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 81. RUSSIA UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY SYSTEMIC TREATMENT, 2018-2030 (USD MILLION)
• TABLE 82. RUSSIA UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 83. SAUDI ARABIA UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY SYSTEMIC TREATMENT, 2018-2030 (USD MILLION)
• TABLE 84. SAUDI ARABIA UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 85. SOUTH AFRICA UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY SYSTEMIC TREATMENT, 2018-2030 (USD MILLION)
• TABLE 86. SOUTH AFRICA UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 87. SPAIN UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY SYSTEMIC TREATMENT, 2018-2030 (USD MILLION)
• TABLE 88. SPAIN UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 89. SWEDEN UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY SYSTEMIC TREATMENT, 2018-2030 (USD MILLION)
• TABLE 90. SWEDEN UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 91. SWITZERLAND UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY SYSTEMIC TREATMENT, 2018-2030 (USD MILLION)
• TABLE 92. SWITZERLAND UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 93. TURKEY UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY SYSTEMIC TREATMENT, 2018-2030 (USD MILLION)
• TABLE 94. TURKEY UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 95. UNITED ARAB EMIRATES UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY SYSTEMIC TREATMENT, 2018-2030 (USD MILLION)
• TABLE 96. UNITED ARAB EMIRATES UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 97. UNITED KINGDOM UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY SYSTEMIC TREATMENT, 2018-2030 (USD MILLION)
• TABLE 98. UNITED KINGDOM UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 99. UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET, FPNV POSITIONING MATRIX, 2022
• TABLE 100. UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SHARE, BY KEY PLAYER, 2022
• TABLE 101. UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET LICENSE & PRICING

The Global Unresectable Hepatocellular Carcinoma Market is forecasted to grow significantly, with a projected USD 1,683.00 million in 2023 at a CAGR of 13.31% and expected to reach a staggering USD 4,054.00 million by 2030.

The Cumulative Impact of COVID-19, the Russia-Ukraine Conflict, and High Inflation is expected to have significant long-term effects on the Global Unresectable Hepatocellular Carcinoma Market. The ongoing research considers the changes in consumer behavior, supply chain disruptions, and government interventions caused by the pandemic. Similarly, the report considers the ongoing political and economic uncertainty in Eastern Europe caused by the Russia-Ukraine Conflict and its potential implications for demand-supply balances, pressure on pricing variants, and import/export and trading. Additionally, the report addresses the impact of High Inflation on the global economy and details fiscal policies measuring and reducing its effects on demand, supply, cash flow, and currency exchange.

Market Segmentation & Coverage:

This research report categorizes the Global Unresectable Hepatocellular Carcinoma Market in order to forecast the revenues and analyze trends in each of following sub-markets:

Based on Systemic Treatment, market is studied across Chemotherapy, Immunotherapy, and Molecularly Targeted Therapy. The Immunotherapy is projected to witness significant market share during forecast period.

Based on End User, market is studied across Cancer Centers, Hospitals, Research institutes, and Specialty Clinics. The Cancer Centers is projected to witness significant market share during forecast period.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom. The Asia-Pacific is projected to witness significant market share during forecast period.

Market Statistics:

The report provides market sizing and forecasts across 7 major currencies - USD, EUR, JPY, GBP, AUD, CAD, and CHF; multiple currency support helps organization leaders to make well-informed decisions. In this report, 2018 to 2021 are considered as historical years, 2022 is base year, 2023 is estimated year, and years from 2024 to 2030 are considered as forecast period.

FPNV Positioning Matrix:

The FPNV Positioning Matrix is essential for assessing the Global Unresectable Hepatocellular Carcinoma Market. It provides a comprehensive evaluation of vendors by examining key metrics within Business Strategy and Product Satisfaction, allowing users to make informed decisions based on their specific needs. This advanced analysis then organizes these vendors into four distinct quadrants, which represent varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital(V).

Market Share Analysis:

The Market Share Analysis offers an insightful look at the current state of vendors in a particular market space. By comparing vendor contributions to overall revenue, customer base, and other key metrics, we can give companies a greater understanding of their performance and what they are up against when competing for market share. The analysis also sheds light on just how competitive any given sector is about accumulation, fragmentation dominance, and amalgamation traits over the base year period studied.

The report provides insights on the following pointers:

1. Market Penetration: Provides comprehensive information on the market offered by the key players

2. Market Development: Provides in-depth information about lucrative emerging markets and analyzes penetration across mature segments of the markets

3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments

4. Market Trends: Provides comprehensive understanding of the Cumulative Impact of COVID-19, the Russia-Ukraine Conflict, and the High Inflation

5. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players

6. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:

1. What is the market size and forecast of the Global Unresectable Hepatocellular Carcinoma Market?

2. What are the inhibiting factors and impact of COVID-19 shaping the Global Unresectable Hepatocellular Carcinoma Market during the forecast period?

3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Unresectable Hepatocellular Carcinoma Market?

4. What is the competitive strategic window for opportunities in the Global Unresectable Hepatocellular Carcinoma Market?

5. What are the technology trends and regulatory frameworks in the Global Unresectable Hepatocellular Carcinoma Market?

6. What is the market share of the leading vendors in the Global Unresectable Hepatocellular Carcinoma Market?

7. What modes and strategic moves are considered suitable for entering the Global Unresectable Hepatocellular Carcinoma Market?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Limitations
• 1.7. Assumptions
• 1.8. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

• 4.1. Introduction
• 4.2. Unresectable Hepatocellular Carcinoma Market, by Systemic Treatment, 2022 vs 2030
• 4.3. Unresectable Hepatocellular Carcinoma Market, by End User, 2022 vs 2030
• 4.4. Unresectable Hepatocellular Carcinoma Market, by Region, 2022 vs 2030

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. High incidence rate of liver carcinoma
    • 5.1.1.2. Increasing cases of liver cancer
    • 5.1.1.3. Major application of chemotherapy
  • 5.1.2. Restraints
    • 5.1.2.1. Limited diagnosis of unresectable hepatocellular carcinoma
  • 5.1.3. Opportunities
    • 5.1.3.1. Advancements for new treatment and therapies
  • 5.1.4. Challenges
    • 5.1.4.1. Limited effects of current therapeutics
• 5.2. Market Trends
• 5.3. Cumulative Impact of COVID-19
• 5.4. Cumulative Impact of Russia-Ukraine Conflict
• 5.5. Cumulative Impact of High Inflation
• 5.6. Porter's Five Forces Analysis
  • 5.6.1. Threat of New Entrants
  • 5.6.2. Threat of Substitutes
  • 5.6.3. Bargaining Power of Customers
  • 5.6.4. Bargaining Power of Suppliers
  • 5.6.5. Industry Rivalry
• 5.7. Value Chain & Critical Path Analysis
• 5.8. Regulatory Framework
• 5.9. Client Customization

6. Unresectable Hepatocellular Carcinoma Market, by Systemic Treatment

• 6.1. Introduction
• 6.2. Chemotherapy
• 6.3. Immunotherapy
• 6.4. Molecularly Targeted Therapy

7. Unresectable Hepatocellular Carcinoma Market, by End User

• 7.1. Introduction
• 7.2. Cancer Centers
• 7.3. Hospitals
• 7.4. Research institutes
• 7.5. Specialty Clinics

8. Americas Unresectable Hepatocellular Carcinoma Market

• 8.1. Introduction
• 8.2. Argentina
• 8.3. Brazil
• 8.4. Canada
• 8.5. Mexico
• 8.6. United States

9. Asia-Pacific Unresectable Hepatocellular Carcinoma Market

• 9.1. Introduction
• 9.2. Australia
• 9.3. China
• 9.4. India
• 9.5. Indonesia
• 9.6. Japan
• 9.7. Malaysia
• 9.8. Philippines
• 9.9. Singapore
• 9.10. South Korea
• 9.11. Taiwan
• 9.12. Thailand
• 9.13. Vietnam

10. Europe, Middle East & Africa Unresectable Hepatocellular Carcinoma Market

• 10.1. Introduction
• 10.2. Denmark
• 10.3. Egypt
• 10.4. Finland
• 10.5. France
• 10.6. Germany
• 10.7. Israel
• 10.8. Italy
• 10.9. Netherlands
• 10.10. Nigeria
• 10.11. Norway
• 10.12. Poland
• 10.13. Qatar
• 10.14. Russia
• 10.15. Saudi Arabia
• 10.16. South Africa
• 10.17. Spain
• 10.18. Sweden
• 10.19. Switzerland
• 10.20. Turkey
• 10.21. United Arab Emirates
• 10.22. United Kingdom

11. Competitive Landscape

• 11.1. FPNV Positioning Matrix
• 11.2. Market Share Analysis, By Key Player
• 11.3. Competitive Scenario Analysis, By Key Player

12. List of Company Mentioned

13. Appendix

• 13.1. Discussion Guide
• 13.2. License & Pricing